Endogenous sex hormones and colorectal cancer survival among men and women
- PMID: 31863463
- PMCID: PMC7895324
- DOI: 10.1002/ijc.32844
Endogenous sex hormones and colorectal cancer survival among men and women
Abstract
Although previous studies have suggested a potential role of sex hormones in the etiology of colorectal cancer (CRC), no study has yet examined the associations between circulating sex hormones and survival among CRC patients. We prospectively assessed the associations of prediagnostic plasma concentrations of estrone, estradiol, free estradiol, testosterone, free testosterone and sex hormone-binding globulin (SHBG) with CRC-specific and overall mortality among 609 CRC patients (370 men and 239 postmenopausal women not taking hormone therapy at blood collection) from four U.S. cohorts. Multivariable hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated using Cox proportional hazard regression. We identified 174 deaths (83 CRC-specific deaths) in men and 106 deaths (70 CRC-specific deaths) in women. In men, higher circulating level of free testosterone was associated with lower risk of overall (the highest vs. lowest tertiles, HR = 0.66, 95% CI, 0.45-0.99, ptrend = 0.04) and possibly CRC-specific mortality (HR = 0.73, 95% CI, 0.41-1.29, ptrend = 0.27). We generally observed nonsignificant inverse associations for other sex steroids, and a positive association for SHBG with CRC-specific mortality among male patients. In women, however, we found a suggestive positive association of estrone with overall (HR = 1.54, 95% CI, 0.92-2.60, ptrend = 0.11) and CRC-specific mortality (HR = 1.96, 95% CI, 1.01-3.84, ptrend = 0.06). Total estradiol, free estradiol and free testosterone were generally suggestively associated with higher risk of mortality among female patients, although not statistically significant. These findings implicated a potential role of endogenous sex hormones in CRC prognosis, which warrant further investigation.
Keywords: cohort study; colorectal cancer; estrogen; estrone; survival; testosterone.
© 2019 UICC.
Conflict of interest statement
Conflict of interest
Dr. Chan reports grants and personal fees from Bayer Pharma AG and personal fees from Pfizer Inc and Janssen. Dr. Fuchs reports grants and personal fees from Agios, Bain Capital, Bayer, Celgene, CytomX, CytomX, Dicerna, Eli Lilly, Entrinsic Health, Entrinsic Health, Five Prime Therapeutics, Genentech, Gilead Sciences, KEW, Merck, Merrimack, Pfizer, Roche, Sanofi, Taiho and Unum.
References
-
- Siegel RL, Miller KD, Fedewa SA, et al. Colorectal cancer statistics, 2017. CA Cancer J Clin 2017;67:177–93. - PubMed
-
- Koo JH, Jalaludin B, Wong SK, et al. Improved survival in young women with colorectal cancer. Am J Gastroenterol 2008;103:1488–95. - PubMed
-
- McArdle CS, McMillan DC, Hole DJ. Male gender adversely affects survival following surgery for colorectal cancer. Br J Surg 2003;90:711–5. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- K24 DK098311/NH/NIH HHS/United States
- P50CA127003/NH/NIH HHS/United States
- R01HL34595/NH/NIH HHS/United States
- P01 CA087969/CA/NCI NIH HHS/United States
- R01CA047988/NH/NIH HHS/United States
- R01 HL034595/HL/NHLBI NIH HHS/United States
- R01HL043851/NH/NIH HHS/United States
- K24 DK098311/DK/NIDDK NIH HHS/United States
- R01HL099355/NH/NIH HHS/United States
- R01 CA097193/CA/NCI NIH HHS/United States
- R01 CA034944/CA/NCI NIH HHS/United States
- R01 HL043851/HL/NHLBI NIH HHS/United States
- R01CA49449/NH/NIH HHS/United States
- U01 CA167552/CA/NCI NIH HHS/United States
- K07 CA188126/NH/NIH HHS/United States
- R01CA40360/NH/NIH HHS/United States
- R01HL080467/NH/NIH HHS/United States
- R01HL26490/NH/NIH HHS/United States
- UM1CA182913/NH/NIH HHS/United States
- R01CA34944/NH/NIH HHS/United States
- UM1 CA186107/CA/NCI NIH HHS/United States
- UM1CA167552/NH/NIH HHS/United States
- R01 CA169141/CA/NCI NIH HHS/United States
- UM1 CA182913/CA/NCI NIH HHS/United States
- R01CA097193/NH/NIH HHS/United States
- R01 HL026490/HL/NHLBI NIH HHS/United States
- R01 CA047988/CA/NCI NIH HHS/United States
- UM1CA186107/NH/NIH HHS/United States
- K07 CA188126/CA/NCI NIH HHS/United States
- P01CA87969/NH/NIH HHS/United States
- R01 HL080467/HL/NHLBI NIH HHS/United States
- UM1 CA167552/CA/NCI NIH HHS/United States
- U01 CA182913/CA/NCI NIH HHS/United States
- R01 CA049449/CA/NCI NIH HHS/United States
- R01 CA040360/CA/NCI NIH HHS/United States
- P50 CA127003/CA/NCI NIH HHS/United States
- RC1 HL099355/HL/NHLBI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
